アキュリスファーマ株式会社（英語名：Aculys Pharma, Inc.）は “Catalyst to Access”（革新的な医療への橋渡しを担う）という理念から創られたAculysを社名とする日本発のバイオベンチャー企業です。神経・精神疾患領域において革新的な医療手段への橋渡し役となり、患者さんとご家族、医療関係者、社会により良い医療を届けるため、欧米諸国から革新的で優れた医薬品を導入し、開発・販売を担いさらに疾患を取り巻く様々な課題に対するソリューションを提供します。
Beyond the development and commercialization of new medicines, Aculys is
committed to the patient experience including the awareness, screening, diagnosis,
treatment of disease and the resolution of surrounding social issues for patients and their
families confronted with neurological and psychiatric disease. The company looks to
form comprehensive solutions through cross-sectional partnerships using new
technologies to enhance the patient experience.
Beyond the development and commercialization of new medicines, Aculys is
committed to the patient experience including the awareness, screening, diagnosis,
treatment of disease and the resolution of surrounding social issues for patients and their
families confronted with neurological and psychiatric disease. The company looks to
form comprehensive solutions through cross-sectional partnerships using new
technologies to enhance the patient experience.
Location: Japan, Kanagawa Prefecture, Fujisawa
Employees: 1-10
Total raised: $84M
Founded date: 2021
Investors 4
| Date | Name | Website |
| - | HBM Partne... | hbmpartner... |
| 02.12.2021 | Catalys Pa... | catalyspac... |
| - | JIC Ventur... | j-vgi.co.j... |
| 04.04.2022 | Spiral Cap... | spiral-cap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.03.2022 | Series B | $24M | - |
| 29.10.2021 | Series A | $60M | - |
Mentions in press and media 11
| Date | Title | Description |
| 01.04.2024 | Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO | ～Hidemasa's appointment bolsters Aculys' position as a leader in the field of CNS in Japan and Asia～ TOKYO, April 1, 2024 /PRNewswire/ -- Aculys Pharma, Inc. ("Aculys"), a clinical-stage biopharmaceutical company focused on commer... |
| 18.10.2023 | Aculys Pharma delivers positive Phase 3 clinical study interim analysis result of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures | These results are from Japan's first domestic Phase 3 clinical trial of an intranasally administered antiepileptic drug for Japanese patients aged 6 to 17 for the treatment of status epilepticus or epileptic seizures that may lead to status... |
| 25.01.2023 | Aculys Pharma Initiates Phase 3 Trial of Pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome | Aculys Pharma, a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, announced the initiation of a phase 3 clinical study in Japan of pitolisant—a histamine H3 receptor anta... |
| 24.01.2023 | Aculys Pharma Initiates a Phase 3 Trial of pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome | This trial is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study (Part 1) and a subsequent multi-center, open-label, long-term extension study (Part 2) to assess the safety and efficacy of pitolisant in the J... |
| 10.11.2022 | Aculys Pharma initiates a phase 3 clinical study of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures | This phase 3 study, conducted in Japan, is a multi-center, open-label study in children with status epilepticus and those at risk for status epilepticus to assess the efficacy and safety of NRL-1. Please visit the following site for detaile... |
| 08.11.2022 | Aculys Pharma initiates a phase 3 clinical study of the histamine H3 receptor antagonist/inverse agonist pitolisant in patients with narcolepsy in Japan | This phase 3 study consists of a multi-institutional double-blind, randomized, placebo-controlled, parallel group-comparison study (Part 1) and an open-label long-term treatment study (Part 2) to assess the efficacy and safety of pitolisant... |
| 28.03.2022 | 神経・精神疾患領域に特化したバイオベンチャー企業であるアキュリスファーマ株式会社へ出資しました | 当社は、Spiral Capital Japan Fund 2号投資事業有限責任組合を通じて、神経・精神疾患領域における革新的な医薬品を開発するアキュリスファーマ株式会社へ出資を行いました。 アキュリスファーマは、睡眠障害に対する治療薬pitolisant及びてんかん発作に対する治療薬である経鼻投与スプレー製剤の開発を進めています。 不眠症やナルコレプシー等の睡眠障害は、日本でも年間10兆円を超える社会・経済的損失を生んでいます。また、てんかん発作も、重積化を防ぐためには早期... |
| 28.03.2022 | Aculys Pharma Closes US$24 Million Series B Financing | Kazunari Tsunaba, Co-founder, Chief Executive Officer and Representative Director of Aculys said, “Advances in medical care, including new anti-epileptic drugs, have enabled many epilepsy patients and caregivers to lead their daily lives wi... |
| 04.02.2022 | Aculys Pharma Initiated a Phase 1 Clinical Trial of pitolisant, a histamine H3 receptor antagonist / inverse agonist, in Japan | Aculys Pharma has an exclusive licensing agreement for the clinical development and commercialization of pitolisant in Japan, and is developing the drug under development code BF2.649. The objective of this clinical trial is to confirm safe... |
| 26.01.2022 | Aculys Pharma signed an exclusive licensing agreement with Neurelis, Inc. for the development and commercialization of VALTOCO® | Aculys Pharma, Inc. (“Aculys Pharma” Headquarters: Fujisawa City, Kanagawa Prefecture, Representative Director and CEO: Kazunari Tsunaba), a new biopharmaceutical company focused on the development and commercialization of new innovative dr... |
Show more